Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data

Kim, Sun Young; Ahn, Hong‐Yup; Shin, Soon Ae; Park, Jong-Heon; Won, Chang Won

doi:10.1016/j.thromres.2017.04.023

Cited by 19 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…be of concern due to the issues reported with coding for VTE and major bleeding in the database [40]. Another retrospective database study by Kim et al [3] found that of the 263,664 patients treated from 2008 to 2012, there was an increase in VTE incidence among those who underwent hip fracture surgery (P ¼ .018).…”

Section: Discussionmentioning

confidence: 99%

Have Venous Thromboembolism Rates Decreased in Total Hip and Knee Arthroplasty?

Warren

Sundaram

Anis

et al. 2020

The Journal of Arthroplasty

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Have Venous Thromboembolism Rates Decreased in Total Hip and Knee Arthroplasty?

Warren

Sundaram

Anis

et al. 2020

The Journal of Arthroplasty

View full text Add to dashboard Cite

“…On the other hand, as PI to prevent VTE, anticoagulant therapy, can increase the risk of bleeding. Close monitoring and balancing are required between the expected reduction in thromboembolic events and any increase in the risk of bleeding . Risk assessment, which takes into account a patient's age, weight, renal function, potential drug‐drug and drug‐disease interactions, and other associated factors, is of great importance considering the widespread use of NSAIDs for orthopaedic trauma patients who often present with one or more risk factors for upper gastrointestinal haemorrhage .…”

Section: Resultsmentioning

confidence: 99%

Impact of pharmaceutical care in the orthopaedic department

Xie

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective In the mid‐1960s, clinical pharmacy developed in the USA, and as the demand for pharmaceutical services continued to grow, their impact began to be taken seriously. However, the participation of clinical pharmacists as members of the multidisciplinary team in the orthopaedic department is still in its infancy, although its role in orthopaedics has not been defined. The object of this study was to identify and discuss the impact of pharmaceutical care in the orthopaedic department. Methods A literature search was conducted on MEDLINE, PubMed, Web of Science, the Cochrane Library and CNKI (China National Knowledge Infrastructure) for papers published between 1998 and 2019, using the keywords pharmacy, pharmacist, and medication or drug combined with orthopaedic. Other available resources were also used to identify relevant articles. Results and discussion Based on the available evidence in 74 articles, it was found that clinical pharmacists play an important role in all aspects of rational use of medications, medication review and reconciliation, monitoring adverse drug events, risk assessment, and medication education and counselling. In addition, clinical pharmacy services were developed to minimize medication errors, adverse drug events and medical costs, but clinical pharmacy is still in its early stages in orthopaedics. What is new and conclusion A multidisciplinary approach should be adopted in the orthopaedic department, as pharmacist interventions can be vital for promoting the safety, effectiveness and cost‐effectiveness of pharmacotherapy. Although pharmacists' contributions to orthopaedics are not yet fully recognized, pharmaceutical services can undoubtedly contribute to both clinical and societal outcomes.

show abstract

“…In an Australian survey, the use of pharmacologic agents other than aspirin decreased from approximately 75% in 2012 to 40% in 2017 [ 60 ]. In a Korean database between 2008–2012, the most commonly prescribed agents for THA were LMWH (34%), heparin (23%), aspirin (19%), warfarin (14%), and novel oral anticoagulants (NOACs) (13%) and for TKA were LMWH (28%), NOACs (22%), aspirin (17%), warfarin (10%), and heparin (9%) [ 61 ]. In the Korean population from 2012–2013, only approximately 66–75% of cases of THA or TKA cases received pharmacologic prophylaxis [ 61 , 62 , 63 ].…”

Section: Pharmacologic Vte Prophylaxismentioning

confidence: 99%

An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020

et al. 2020

View full text Add to dashboard Cite

Patients undergoing total hip and knee arthroplasty are at high risk for venous thromboembolism (VTE) with an incidence of approximately 0.6–1.5%. Given the high volume of these operations, with approximately one million performed annually in the U.S., the rate of VTE represents a large absolute number of patients. The rate of VTE after total hip arthroplasty has been stable over the past decade, although there has been a slight reduction in the rate of deep venous thrombosis (DVT), but not pulmonary embolism (PE), after total knee arthroplasty. Over this time, there has been significant research into the optimal choice of pharmacologic VTE prophylaxis for individual patients, with the objective to reduce the rate of VTE while minimizing adverse side effects such as bleeding. Recently, aspirin has emerged as a promising prophylactic agent for patients undergoing arthroplasty due to its similar efficacy and good safety profile compared to other pharmacologic agents. However, there is no evidence to date that clearly demonstrates the superiority of any given prophylactic agent. Therefore, this review discusses (1) the current prevalence and trends in VTE after total hip and knee arthroplasty and (2) provides an update on pharmacologic VTE prophylaxis in regard to aspirin usage.

show abstract

Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data

Cited by 19 publications

References 19 publications

Have Venous Thromboembolism Rates Decreased in Total Hip and Knee Arthroplasty?

Have Venous Thromboembolism Rates Decreased in Total Hip and Knee Arthroplasty?

Impact of pharmaceutical care in the orthopaedic department

An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020

Contact Info

Product

Resources

About